News | July 08, 2008

Cryoablation Just as Effective as Radiofrequency in Treating Atrial Flutter

July 9, 2008 - New research shows catheter cryoablation is comparably effective to radiofrequency catheter ablation for the treatment of atrial flutter (AFL) and may have some safety advantages over the use of radiofrequency.

The findings are detailed in a study published in the July edition of the HeartRhythm Journal, the journal of the Heart Rhythm Society. This is the first large, multi-center study to prove the acute and long-term safety and efficacy of catheter based-cryoablation for the treatment of AFL, reporting six-month follow-up results for 160 patients.

AFL is characterized by a rapid heartbeat and is caused by a single electrical wave that circulates very rapidly in the atrium, about 300 times a minute, leading to a very fast, steady heartbeat. This rapid heartbeat disrupts the pumping of blood to the heart and complications of atrial flutter can potentially lead to a stroke.

Currently, radiofrequency catheter ablation is a very common and effective treatment of AFL, with cure rates around 95 percent. However, radiofrequency catheter ablation can cause serious side effects, such as coagulum formation or endocardial charring which can lead to potential long-term health complications. Catheter-based cryoablation is said to be a viable and safer alternative to radiofrequency catheter ablation, but its efficiency in treating AFL had not been systematically evaluated in a large clinical trial until now.

The study led by Gregory K. Feld, M.D., of the University of California, San Diego (UCSD) School of Medicine, performed catheter-based cryoablation at 12 medical centers in 160 patients with cavotricuspid isthmus-dependent AFL. Patients were evaluated at one, three and six months and underwent weekly and symptomatic event monitoring. The study revealed 90.2 percent of patients remained clinically free of AFL, proving the effectiveness of cryoablation in the treatment of AFL.

“A study of this size, performed at multiple centers, better validates the safety and efficacy of a device for arrhythmia treatment, compared to smaller, single center studies,” Feld said. “The validity of this large multi-center study proves that cryoablation is reliable treatment of atrial flutter, and is further supported by the many safety advantages cryoablation offers over radiofrequency treatment.”

As shown in this study and others, in addition to the newly proven effectiveness of cryoablation in the treatment of AFL, cryoablation also presents a number of safety advantages over radiofrequency, including: less pain, less risk of coagulum formation, less risk of causing heart block and no risk of causing pulmonary vein stenosis which is the narrowing of the vein caused by heating.

For more information:

Related Content

Stereotaxis Receives Regulatory Approval of e-Contact Module in Canada
Technology | Ablation Systems| December 08, 2017
December 7, 2017 — Stereotaxis Inc.
CardioFocus Announces European CE Mark Approval of HeartLight Excalibur Balloon
Technology | Ablation Systems| October 10, 2017
October 10, 2017 — CardioFocus Inc. recently announced the European CE Mark approval of the HeartLight Excalibur Ball
The Apama Radiofrequency (RF) Balloon Catheter System.
News | Ablation Systems| October 02, 2017
October 2, 2017 — Boston Scientific announced a definitive agreement to acquire Apama Medical Inc., a privately-held
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Medtronic Announces First Enrollments in STOP AF First Clinical Trial
News | Ablation Systems| July 24, 2017
Medtronic plc recently announced first enrollments in the STOP AF First clinical trial. The trial will evaluate the...
Biosense Webster multi-electrode RF ablation balloon

Biosense Webster's multi-electrode RF ablation balloon with irrigation. The system allows operators to change the energy levels of each electrode to avoid damaging sensitive underlying critical structures like the esophagus or phrenic nerve.

Feature | Ablation Systems| May 17, 2017 | Dave Fornell
May 17, 2017 – Clinical trial results from a first-in-human study evaluating the acute feasibility of an investigatio
Abbott Announces CE Mark for New Cardiac Ablation Catheter
News | Ablation Systems| May 10, 2017
Abbott announced CE Mark of the TactiCath Contact Force Ablation Catheter, Sensor Enabled, developed to make it easier...
Medtronic, expanded indication, Freezor Xtra Cryoablation Catheter, AVNRT, atrioventricular nodal re-entrant tachycardia
Technology | Ablation Systems| February 16, 2017
Medtronic plc announced the U.S. Food and Drug Administration (FDA) has approved its Freezor Xtra Cryoablation Catheter...
CardioFocus, HeartLight Excalibur Balloon, 22nd Annual AF Symposium, atrial fibrillation, initial clinical evaluation
News | Ablation Systems| January 25, 2017
CardioFocus Inc. recently announced the initial clinical evaluation of the HeartLight Excalibur Balloon, a next-...
catheter ablations, atrial fibrillation, stroke risk, Intermountain Medical Center Heart Institute study, AHA Scientific Sessions, American Heart Association
News | Ablation Systems| November 14, 2016
Atrial fibrillation patients with a prior history of stroke who undergo catheter ablation lower their long-term risk of...
Overlay Init